INOVOTION has collaborated with multiples research teams, and the publications cited provide information about INOVOTION's technology. However if you have any questions or comment, feel free to contact us, our scientific team will be delighted to help you.
Iman W. Achkar,Sara Kader, Shaima S. Dib, Kulsoom Junejo, Salha Bujassoum Al-Bader, Shahina Haya, Aditya M. Bhagwat, Xavier Rousset, Yan Wan, Jean Viallet, Karsten Suhre and Anna Halama
Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo
Metabolites 2020, 10(7), 268
Download
Laurie Signetti, Nelli Elizarov, Méliné Simsir, Agnès Paquet, Dominique Douguet, Fabien Labbal, Delphine Debayle, Audrey Di Giorgio, Valérie Biou, Christophe Girard, Maria Duca, Lionel Bretillon, Corine Bertolotto, Bernard Verrier, Stéphane Azoulay and Isabelle Mus-Veteau
Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BrafV600E Melanoma
Cancers 2020, 12(6), 1500
Download
Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.
Invest New Drugs (2019 Feb 19) pp 1-11
Arafat K, Al Kubaisy E, Sulaiman S, Karam S, M, Al Natour Z, Hassan A, H, Attoub S.
SMARCAD1 in Breast Cancer Progression.
Cell Physiol Biochem 2018;50:489-500
P. Gilson, M. Couvet, L. Vanwonterghem, M. Henry, J. Vollaire, V. Baulin, M. Werner, A. Orlowska, V. Josserand, F. Mahuteau-Betzer, L. Lafanechère, J-L. Coll, B. Busser, A. Hurbin.
The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.
Biochemical Pharmacology (2018)
Gilson P, Josa-Prado F, Beauvineau C, Naud-Martin D, Vanwonterghem L, Mahuteau-Betzer F, Moreno A5, Falson P, Lafanechère L, Frachet V, Coll JL, Fernando Díaz J, Hurbin A, and Busser B.
Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.
Sci Rep. 2017 Aug 31; 7:10209
SMARCAD1 knockdown uncovers its role in breast cancer cell migration, invasion, and metastasis.
Expert Opinion on Therapeutic Targets (2016), 20:9, 1035-1043
El Hasasna H, Saleh A, Samri HA, Athamneh K, Attoub S, Arafat K, Benhalilou N, Alyan S, Viallet J, Dhaheri YA, Eid A, Iratni R.
Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through inhibition of STAT3, NFκB and nitric oxide pathways.
Sci Rep. 2016 Feb 18;6:21144.
Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J, Allioli N.
Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.
Oncogene. 2015 May 28;34(22):2846-55.
Mikaelian I, Malek M, Gadet R, Viallet J, Garcia A, Girard-Gagnepain A, Hesling C, Gillet G, Gonzalo P, Rimokh R, Billaud M.
Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism.
Cancer Res. 2013 Nov 15;73(22):6621-31.
Al Dhaheri Y, Attoub S, Arafat K, Abuqamar S, Viallet J, Saleh A, Al Agha H, Eid A, Iratni R.
Anti-metastatic and anti-tumor growth effects of Origanum majorana on highly metastatic human breast cancer cells: inhibition of NFκB signaling and reduction of nitric oxide production.
PLoS One. 2013 Jul 10;8(7):e68808.
Prudent R, Vassal-Stermann É, Nguyen CH, Mollaret M, Viallet J, Desroches-Castan A, Martinez A, Barette C, Pillet C, Valdameri G, Soleilhac E, Di Pietro A, Feige JJ, Billaud M, Florent JC, Lafanechère L.
Azaindole derivatives are inhibitors of microtubule dynamics, with anticancer and anti-angiogenic activities.
Br J Pharmacol. 2013 Feb;168(3):673-85.
